• Influence of co-morbidity on renal function assessment by Cockcroft-Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy.

      Hubner, Richard A; Goldstein, R; Mitchell, S; Jones, A; Ashley, S; O'Brien, M E R; Popat, S; Dept Medical Oncology, Christie Hospital, Manchester M20 4BX, UK. (2011-09)
      Creatinine clearance (CrCl) estimation by Cockcroft-Gault calculation (CG) often replaces measurement of glomerular filtration rate (GFR) by [(51)Cr]-ethylenediaminetetraacetic acid clearance (EDTA). Co-morbidity, age, and renal impairment influence the accuracy of CG, whilst the relationship between CG and EDTA has been poorly assessed in lung cancer patients, a population significantly affected by these covariates.
    • Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.

      Ring, A; Sestak, I; Baum, M; Howell, Anthony; Buzdar, A; Dowsett, M; Forbes, J F; Cuzick, J; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, BN2 5BE, United Kingdom. (2011-11-10)
      The Arimidex, Tamoxifen Alone or in Combination (ATAC) study was a double-blind randomized trial in which postmenopausal women with early-stage breast cancer were assigned to receive anastrozole, tamoxifen, or the combination. We have conducted a retrospective analysis to examine the effects of comorbidities and age on treatment received, breast cancer-related mortality, and competing causes of mortality.
    • A longitudinal investigation of posttraumatic stress disorder in patients with ovarian cancer.

      Gonçalves, V; Jayson, Gordon C; Tarrier, N; Division of Clinical Psychology, School of Psychological Sciences, University of Manchester, Manchester, UK. (2011-05)
      Exposure to the aggressive and life-threatening nature of ovarian cancer and its treatment is potentially traumatic. However, little is known about the occurrence of posttraumatic stress disorder (PTSD) in these patients.
    • Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.

      Evans, D Gareth R; Lalloo, Fiona; Ashcroft, Linda; Shenton, Andrew; Clancy, Tara; Baildam, Andrew D; Brain, Anne; Hopwood, Penelope; Howell, Anthony; Regional Genetic Service, The University of Manchester, St.Mary's Hospital, Manchester, United Kingdom. Gareth.evans@cmft.nhs.uk (2009-08)
      PURPOSE: The uptake of risk-reducing surgery in women at increased risk of breast and ovarian cancer is highly variable between countries and centers within countries. We have investigated the rate, timing, and age of uptake of surgery in the northwest of England to report the results after up to 7 years in a Regional Genetics center. METHODS: Uptake was documented in 211 known unaffected BRCA1/2 mutation carriers from 509 families and in 3,515 women at >25% lifetime risk of breast cancer without known mutations. RESULTS: Of the 211 mutation carriers, 40% opted for bilateral risk-reducing mastectomy (BRRM) and 45% underwent bilateral risk-reducing salpingo-oophorectomy (BRRSPO). Uptake of BRRM was significantly related to lifetime risk and age but continued over several years. In women not known to carry a BRCA mutation, 6.4% of women at 40% to 45% lifetime risk, 2.5% of women at 33% to 39% lifetime risk, and 1.8% of women at 25% to 32% lifetime risk underwent BRRM (P < 0.005). BRRSPO uptake was greater in BRCA1 (52%) than BRCA2 (28%) carriers but in both groups tended to occur within the first 2 years after gene test (except in the youngest age group) and in women between the ages of 35 and 45. CONCLUSION: To truly assess the uptake of risk-reducing surgery, longer-term follow-up is necessary particularly in younger women who are likely to delay BRRSPO. Careful risk counseling does seem to influence women's decisions for surgery, although the effect is not immediate.